TY - JOUR
T1 - Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization
AU - Tolan, Nicole V.
AU - Krasowski, Matthew D.
AU - Mathias, Patrick C.
AU - Wiencek, Joesph R.
AU - Babic, Nikolina
AU - Chai, Peter R.
AU - Chambliss, Allison B.
AU - Choucair, Ibrahim
AU - Demetriou, Christiana A.
AU - Erickson, Timothy B.
AU - Feldhammer, Matthew
AU - French, Deborah
AU - Hayes, Bryan D.
AU - Kang, Phillip
AU - El-Khoury, Joe M.
AU - Knezevic, Claire E.
AU - Monte, Andrew
AU - Nerenz, Robert D.
AU - Okorodudu, Anthony O.
AU - Roper, Stephen M.
AU - Saitman, Alec
AU - Thiriveedhi, Vamsi
AU - Uljon, Sacha N.
AU - Vest, Alexis
AU - Woodworth, Alison
AU - Yu, Min
AU - Melanson, Stacy E.F.
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Background: Many states in the United States have progressed towards legalization of marijuana including decriminalization, medicinal and/or recreational use. We studied the impact of legalization on cannabis-related emergency department visits in states with varying degrees of legalization. Methods: Seventeen healthcare institutions in fifteen states (California, Colorado, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Missouri, New Hampshire, Oregon, South Carolina, Tennessee, Texas, Washington) participated. Cannabinoid immunoassay results and cannabis-related International Classification of Diseases (ninth and tenth versions) codes were obtained for emergency department visits over a 3- to 8-year period during various stages of legalization: no state laws, decriminalized, medical approval before dispensaries, medical dispensaries available, recreational approval before dispensaries and recreational dispensaries available. Trends and monthly rates of cannabinoid immunoassay and cannabis-related International Classification of Diseases code positivity were determined during these legalization periods. Results: For most states, there was a significant increase in both cannabinoid immunoassay and International Classification of Diseases code positivity as legalization progressed; however, positivity rates differed. The availability of dispensaries may impact positivity in states with medical and/or recreational approval. In most states with no laws, there was a significant but smaller increase in cannabinoid immunoassay positivity rates. Conclusions: States may experience an increase in cannabis-related emergency department visits with progression toward marijuana legalization. The differences between states, including those in which no impact was seen, are likely multifactorial and include cultural norms, attitudes of local law enforcement, differing patient populations, legalization in surrounding states, availability of dispensaries, various ordering protocols in the emergency department, and the prevalence of non-regulated cannabis products.
AB - Background: Many states in the United States have progressed towards legalization of marijuana including decriminalization, medicinal and/or recreational use. We studied the impact of legalization on cannabis-related emergency department visits in states with varying degrees of legalization. Methods: Seventeen healthcare institutions in fifteen states (California, Colorado, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Missouri, New Hampshire, Oregon, South Carolina, Tennessee, Texas, Washington) participated. Cannabinoid immunoassay results and cannabis-related International Classification of Diseases (ninth and tenth versions) codes were obtained for emergency department visits over a 3- to 8-year period during various stages of legalization: no state laws, decriminalized, medical approval before dispensaries, medical dispensaries available, recreational approval before dispensaries and recreational dispensaries available. Trends and monthly rates of cannabinoid immunoassay and cannabis-related International Classification of Diseases code positivity were determined during these legalization periods. Results: For most states, there was a significant increase in both cannabinoid immunoassay and International Classification of Diseases code positivity as legalization progressed; however, positivity rates differed. The availability of dispensaries may impact positivity in states with medical and/or recreational approval. In most states with no laws, there was a significant but smaller increase in cannabinoid immunoassay positivity rates. Conclusions: States may experience an increase in cannabis-related emergency department visits with progression toward marijuana legalization. The differences between states, including those in which no impact was seen, are likely multifactorial and include cultural norms, attitudes of local law enforcement, differing patient populations, legalization in surrounding states, availability of dispensaries, various ordering protocols in the emergency department, and the prevalence of non-regulated cannabis products.
KW - ICD codes
KW - Marijuana
KW - Tetrahydrocannabinol
KW - cannabis
KW - decriminalization
KW - legalization
KW - recreational use
KW - urine drug screen
UR - http://www.scopus.com/inward/record.url?scp=85157976345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85157976345&partnerID=8YFLogxK
U2 - 10.1080/15563650.2023.2177552
DO - 10.1080/15563650.2023.2177552
M3 - Article
C2 - 37129223
AN - SCOPUS:85157976345
SN - 1556-3650
VL - 61
SP - 248
EP - 259
JO - Clinical Toxicology
JF - Clinical Toxicology
IS - 4
ER -